Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 17, Issue 1, 2012, Pages

  Brailo, Vlaho ^a   Vucicevic Boras, Vanja ^a   Lukac, Josip ^b   Biocina Lukenda, Dolores ^c   Zilic Alajbeg, Iva ^a   Milenovic, Aleksandar ^d   Balija, Melita ^e  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c UNIVERSITY OF SPLIT   (Croatia)

^d University of Zagreb   (Croatia)

^e CROATIAN INSTITUTE OF TRANSFUSION MEDICINE   (Croatia)

Author keywords

Cancer; Cytokines; Leukoplakia; Oral

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; EDENTULOUSNESS; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPLAKIA; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; SALIVA LEVEL; SMOKING;

FEMALE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH NEOPLASMS; SALIVA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855661400     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: 10.4317/medoral.17323     Document Type: Article

References (30)

1. Axéll T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med. 1996;25:49-54.
2. Van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009;45:317-23.
3. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2006;42:461-74.
4. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-basedpopulation of 166 patients with oral leukoplakia from The Netherlands. OralOncol. 1998;34:270-5.
5. Van der Waal I, Schepman KP, van der Meij EH, Smeele LE. Oral leukoplakia: a clinicopathological review. Oral Oncol. 1997;33:291-301.
6. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095-147.
7. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, et al. Effects of micro environment-and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer. 2006;42:751-9.
8. Oyama N, Iwatsuki K, Homma Y, Kaneko F. Induction of transcription factor AP-2 by inflammatory cytokines in human keratinocytes. J Invest Dermatol. 1999;113:600-6.
9. Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 2005;65:4673-82.
10. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35-53.
11. Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, et al. Tumor necrosis factor alpha is a potent endogenous mutagen that promotes cellulartransformation. Cancer Res. 2006;66:11565-70.
12. Brill AH. The TNM system for clinical staging of oral malignant tumors. Otolaryngol Clin North Am. 1979;12:69-71.
13. Wu-Wang CY, Patel M, Feng J, Milles M, Wang SL. Decreased levels of salivary prostaglandin E2 and epidermal growth factor in recurrent aphthous stomatitis. Arch Oral Biol. 1995;40:1093-8.
14. Ainamo J, Barmes D, Beagrie G, Cutress T, Martin J, Sardo-Infirri J. Development of the World Health Organization (WHO) community periodontal index of treatment needs (CPITN). Int Dent J. 1982;32:281-91.
15. Arellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, et al. Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis. 2008;14:705-12.
16. Katakura A, Kamiyama I, Takano N, Shibahara T, Muramatsu T, Ishihara K, et al. Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll. 2007;48:199-203.
17. Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol. 2005;114:278-83.
18. Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog. 2005;44:77-82.
19. SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A. Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2008;13:E292-5.
20. Vucicević Boras V, Cikes N, Lukać J, Virag M, Cekić-Arambasin A. Salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with oral squamous cell carcinoma. Minerva Stomatol. 2005;54:569-73.
21. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130:929-35.
22. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999;5:1369-79.
23. Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev. 2008;17:3450-6.
24. Jablonska E, Piotrowski L, Grabowska Z. Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer. Pathol Oncol Res. 1997;3:126-129.
25. Hathaway B, Landsittel DP, Gooding W, Whiteside TL, Grandis JR, Siegfried JM, et al. Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope. 2005;115:522-7.
26. Hoffmann TK, Sonkoly E, Homey B, Scheckenbach K, Gwosdz C, Bas M, et al. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck. 2007;29:472-8.
27. Frodge BD, Ebersole JL, Kryscio RJ, Thomas MV, Miller CS. Bone remodeling biomarkers of periodontal disease in saliva. J Periodontol. 2008;79:1913-9.
28. Miller CS, King CP Jr, Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease: a cross-sectional study. J Am Dent Assoc. 2006;137:322-9.
29. Brailo V, Vucićević-Boras V, Cekić-Arambasin A, Alajbeg IZ, Milenović A, Lukac J. The significance of salivary interleukin 6 and tumor necrosis factor alpha in patients with oral leukoplakia. Oral Oncol. 2006;42:370-3.
30. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006;17:141-6.